Patents Assigned to XINTHERA, INC.
  • MK2 inhibitors and uses thereof
    Patent number: 12545662
    Abstract: Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: February 10, 2026
    Assignee: XinThera, Inc.
    Inventors: Lynnie Trzoss, Qing Dong, Stephen W. Kaldor, Robert L. Hoffman
  • Substituted pyridines as PARP1 inhibitors
    Patent number: 12421241
    Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: May 2, 2024
    Date of Patent: September 23, 2025
    Assignee: XinThera, Inc.
    Inventors: Robert L. Hoffman, Porino Jinjo Va, Joseph Robert Pinchman, Qing Dong, Stephen W. Kaldor
  • PARP1 inhibitors and uses thereof
    Patent number: 12384780
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: July 18, 2024
    Date of Patent: August 12, 2025
    Assignee: XinThera, Inc.
    Inventors: Qing Dong, Robert L. Hoffman, Stephen W. Kaldor, Joseph Robert Pinchman, Lynnie Trzoss, Porino Jinjo Va
  • Pyridinone MK2 inhibitors and uses thereof
    Patent number: 12139462
    Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: November 12, 2024
    Assignee: XinThera, Inc.
    Inventors: Robert L. Hoffman, Lynnie Trzoss, Qing Dong, Stephen W. Kaldor
  • MK2 inhibitors and uses thereof
    Patent number: 11987574
    Abstract: Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Grant
    Filed: July 13, 2023
    Date of Patent: May 21, 2024
    Assignee: XinThera, Inc.
    Inventors: Lynnie Trzoss, Qing Dong, Stephen W. Kaldor, Robert L. Hoffman
  • PARP1 inhibitors and uses thereof
    Patent number: 11939329
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: March 26, 2024
    Assignee: XinThera, Inc.
    Inventors: Robert L. Hoffman, Porino Jinjo Va, Joseph Robert Pinchman, Lynnie Trzoss, Qing Dong, Stephen W. Kaldor
  • Azetidine and pyrrolidine PARP1 inhibitors and uses thereof
    Patent number: 11802128
    Abstract: Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors.
    Type: Grant
    Filed: February 28, 2023
    Date of Patent: October 31, 2023
    Assignee: Xinthera, Inc.
    Inventors: Robert L. Hoffman, Qing Dong, Stephen W. Kaldor, Lynnie Trzoss, Porino Jinjo Va
  • Substituted pyridines as PARP1 inhibitors
    Patent number: 11795173
    Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors.
    Type: Grant
    Filed: April 27, 2023
    Date of Patent: October 24, 2023
    Assignee: Xinthera, Inc.
    Inventors: Robert L Hoffman, Porino Jinjo Va, Joseph Robert Pinchman, Qing Dong, Stephen W. Kaldor
  • Pyridinone MK2 inhibitors and uses thereof
    Patent number: 11685719
    Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Grant
    Filed: July 7, 2022
    Date of Patent: June 27, 2023
    Assignee: XINTHERA, INC.
    Inventors: Robert L. Hoffman, Lynnie Trzoss, Qing Dong, Stephen W. Kaldor
  • MK2 inhibitors and uses thereof
    Patent number: 11680056
    Abstract: Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: June 20, 2023
    Assignee: XINTHERA, INC.
    Inventors: Lynnie Trzoss, Qing Dong, Stephen W. Kaldor, Robert L. Hoffman
  • PARP1 inhibitors and uses thereof
    Patent number: 11591331
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: February 28, 2023
    Assignee: XINTHERA, INC.
    Inventors: Lynnie Trzoss, Qing Dong, Stephen W. Kaldor